We are interested in how cellular signals are propagated through interaction networks at the RNA-protein interface, and how these networks malfunction during cancer and disease. While much of the human genome is transcribed into RNA, only a small portion (< 5%) encodes protein; the remainder of the transcriptome includes various types of small and long noncoding RNAs whose mechanisms are not fully understood. Some long noncoding RNAs associate with chromatin in the nucleus as a part of larger networked ribonucleoprotein granules, where they regulate gene expression and RNA processing. In cancer cells, changes in RNA-binding protein stoichiometry and modification status reorganize the interaction networks of noncoding RNAs, resulting in altered functions. Our vision is to leverage RNA and protein sequencing technologies to characterize these altered interaction network profiles in cancer cells and generate novel therapeutic strategies that target the RNA-protein interface.